Picture of IRIDEX logo

IRIX — IRIDEX News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

Iridex Corp Reports Results For The Quarter Ended In June: Earnings Summary

* IRIDEX Corp  IRIX.OQ  reported a quarterly adjusted loss
of 16
cents​​ per share for the quarter ended in June, higher than the
same quarter last year, when the company reported EPS of -17
cents.  The lone analyst forecast for the quarter was for a loss
of 12 cents per share. 
    * Revenue fell 1.7% to $12.63 million from a year ago;
analysts
expected $12.80 million. 
    * IRIDEX Corp's reported EPS for the quarter was a loss
of 16
cents​.
    * The company reported a quarterly loss of $2.68 million.
    * IRIDEX Corp shares had fallen by 15.7% this quarter and
lost 35.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 9.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "hold"

Wall Street's median 12-month price target for IRIDEX Corp is
$2.00 
This summary was machine generated from LSEG data August 8 at
09:52 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.12          -0.16          Missed
 Mar. 31 2024      -0.12          -0.21          Missed
 Dec. 31 2023      -0.05          -0.18          Missed
 Sep. 30 2023      -0.12          -0.11          Beat

Recent news on IRIDEX

See all news